H. B. El-serag and . Hepatocellular, N Engl J Med, vol.365, pp.1118-1127, 2011.

A. Forner, J. M. Llovet, J. Bruix, and . Hepatocellular, Lancet, vol.379, pp.1245-1255, 2012.

A. Vogel, A. Cervantes, I. Chau, D. B. Llovet, J. Meyer et al., Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.29, pp.238-255, 2018.

, European Association for the Study of the LiverEuropean Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma, J Hepatol, vol.69, pp.182-236, 2018.

J. Calderaro, G. Couchy, S. Imbeaud, G. Amaddeo, E. Letouze et al., Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification, J Hepatol, 2017.

P. S. Tan, S. Nakagawa, N. Goossens, A. Venkatesh, T. Huang et al., Clinicopathological indices to predict hepatocellular carcinoma molecular classification, Liver Int, 2015.

V. Audard, G. Grimber, C. Elie, B. Radenen, A. Audebourg et al., Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations, J Pathol, vol.212, pp.345-352, 2007.

R. Macsween, A. D. Burt, B. Portmann, and L. D. Ferrell, MacSween's pathology of the liver

, Bosman FTWorld Health OrganizationInternational Agency for Research on Cancer. WHO classification of tumours of the digestive system, 2010.

D. Tommaso, L. Franchi, G. Park, Y. N. Fiamengo, B. Destro et al., Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis, Hepatology, vol.45, pp.725-734, 2007.

V. Paradis, Histopathology of hepatocellular carcinoma. Recent Results Cancer Res, vol.190, pp.21-32, 2013.

J. Zucman-rossi, A. Villanueva, J. C. Nault, and J. M. Llovet, Genetic landscape and biomarkers of hepatocellular carcinoma, Gastroenterology, vol.149, pp.1226-1239, 2015.

S. M. Ahn, S. J. Jang, J. H. Shim, D. Kim, S. M. Hong et al., A genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification, Hepatology, 2014.

K. Schulze, S. Imbeaud, E. Letouze, L. B. Alexandrov, J. Calderaro et al., Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nat Genet, vol.47, pp.505-511, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01159736

C. Guichard, G. Amaddeo, S. Imbeaud, Y. Ladeiro, L. Pelletier et al., Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma, Nat Genet, vol.44, pp.694-698, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00719917

Y. Totoki, K. Tatsuno, K. R. Covington, H. Ueda, C. J. Creighton et al., Trans-ancestry mutational landscape of hepatocellular carcinoma genomes, Nat Genet, vol.46, pp.1267-1273, 2014.

J. C. Nault, M. Mallet, C. Pilati, J. Calderaro, P. Bioulac-sage et al., High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions, Nat Commun, vol.4, p.2218, 2013.

Y. Hoshida, S. M. Nijman, M. Kobayashi, J. A. Chan, J. P. Brunet et al., Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma, Cancer Res, vol.69, pp.7385-7392, 2009.

S. Boyault, D. S. Rickman, A. De-reynies, C. Balabaud, S. Rebouissou et al., Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets, Hepatology, vol.45, pp.42-52, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00130313

, Cancer Genome Atlas Research Network, Cancer Genome Atlas Research N. Comprehensive and integrative genomic characterization of hepatocellular carcinoma, Cell, vol.169, pp.1327-1341, 1323.

D. Y. Chiang, A. Villanueva, Y. Hoshida, J. Peix, P. Newell et al., Focal gains of VEGFA and molecular classification of hepatocellular carcinoma, Cancer Res, vol.68, pp.6779-6788, 2008.

J. M. Llovet, R. Montal, D. Sia, and R. S. Finn, Molecular therapies and precision medicine for hepatocellular carcinoma, Nat Rev Clin Oncol, vol.15, pp.599-616, 2018.

J. M. Llovet, A. Villanueva, A. Lachenmayer, and R. S. Finn, Advances in targeted therapies for hepatocellular carcinoma in the genomic era, Nat Rev Clin Oncol, vol.12, p.436, 2015.

J. S. Lee, I. S. Chu, J. Heo, D. F. Calvisi, Z. Sun et al., Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling, Hepatology, vol.40, pp.667-676, 2004.

S. P. Monga, Beta-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis, Gastroenterology, vol.148, pp.1294-1310, 2015.

A. Gougelet, C. Torre, P. Veber, C. Sartor, L. Bachelot et al., T-cell factor 4 and beta-catenin chromatin occupancies pattern zonal liver metabolism in mice, Hepatology, vol.59, pp.2344-2357, 2014.

A. Ueno, Y. Masugi, K. Yamazaki, M. Komuta, K. Effendi et al., OATP1B3 expression is strongly associated with Wnt/beta-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma, J Hepatol, vol.61, pp.1080-1087, 2014.

M. Ziol, N. Pote, G. Amaddeo, A. Laurent, J. C. Nault et al., Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance, Hepatology, vol.68, pp.103-112, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01744935

L. Zhang, N. Yang, J. W. Park, D. Katsaros, S. Fracchioli et al., Tumorderived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer, Cancer Res, vol.63, pp.3403-3412, 2003.

D. Gerald, S. Chintharlapalli, H. G. Augustin, and L. E. Benjamin, Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy, Cancer Res, vol.73, pp.1649-1657, 2013.

J. Y. Seok, D. C. Na, H. G. Woo, M. Roncalli, S. M. Kwon et al., A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition, Hepatology, vol.55, pp.1776-1786, 2012.

M. Salomao, W. M. Yu, R. S. Brown, J. C. Emond, and J. H. Lefkowitch, Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH, Am J Surg Pathol, vol.34, pp.1630-1636, 2010.

M. Salomao, H. Remotti, R. Vaughan, A. B. Siegel, J. H. Lefkowitch et al., The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis, Hum Pathol, vol.43, pp.737-746, 2012.

J. S. Lee, J. E. Yoo, H. Kim, H. Rhee, M. J. Koh et al., Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma, PLoS One, vol.12, p.171922, 2017.

S. Ando, J. Shibahara, A. Hayashi, and M. Fukayama, beta-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study, Virchows Archiv, 2015.

K. R. Patel, T. C. Liu, N. Vaccharajani, W. C. Chapman, and E. M. Brunt, Characterization of inflammatory (lymphoepithelioma-like) hepatocellular carcinoma: a study of 8 cases, Arch Pathol Lab Med, vol.138, pp.1193-1202, 2014.

A. Solinas and D. F. Calvisi, Lessons from rare tumors: hepatic lymphoepithelioma-like carcinomas, World J Gastroenterol, vol.21, pp.3472-3479, 2015.

A. W. Chan, J. H. Tong, Y. Pan, S. L. Chan, G. L. Wong et al., Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome, Am J Surg Pathol, vol.39, pp.304-312, 2015.

I. Labgaa, A. Stueck, and S. C. Ward, Lymphoepithelioma-like carcinoma in liver, Am J Pathol, vol.187, pp.1438-1444, 2017.

J. Calderaro, B. Rousseau, G. Amaddeo, M. Mercey, C. Charpy et al., Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features, Hepatology, vol.64, pp.2038-2046, 2016.

S. D. Brown, R. L. Warren, E. A. Gibb, S. D. Martin, J. J. Spinelli et al., Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival, Genome Res, vol.24, pp.743-750, 2014.

Z. Song, G. Cheng, C. Xu, W. Wang, Y. Shao et al., Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer, Lung Cancer, vol.118, pp.57-61, 2018.

Y. K. Chae, J. F. Anker, P. Bais, S. Namburi, F. J. Giles et al., Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma, Oncotarget, vol.9, pp.7949-7960, 2018.

S. Turajlic, K. Litchfield, H. Xu, R. Rosenthal, N. Mcgranahan et al., Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis, Lancet Oncol, vol.18, pp.1009-1021, 2017.

N. Mcgranahan, A. J. Furness, R. Rosenthal, S. Ramskov, R. Lyngaa et al., Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, vol.351, pp.1463-1469, 2016.

D. Sia, Y. Jiao, I. Martinez-quetglas, O. Kuchuk, C. Villacorta-martin et al., Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features, Gastroenterology, vol.153, pp.812-826, 2017.

A. Durnez, C. Verslype, F. Nevens, J. Fevery, R. Aerts et al., The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin, Histopathology, vol.49, pp.138-151, 2006.

J. S. Lee, J. Heo, L. Libbrecht, I. S. Chu, P. Kaposi-novak et al., A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells, Nat Med, vol.12, pp.410-416, 2006.

A. Holczbauer, V. M. Factor, J. B. Andersen, J. U. Marquardt, D. E. Kleiner et al., Modeling pathogenesis of primary liver cancer in lineagespecific mouse cell types, Gastroenterology, vol.145, pp.221-231, 2013.

J. P. Lai, A. Conley, B. S. Knudsen, and M. Guindi, Hypoxia after transarterial chemoembolization may trigger a progenitor cell phenotype in hepatocellular carcinoma, Histopathology, vol.67, pp.442-450, 2015.

Z. Zeng, J. Ren, O. Neil, M. Zhao, J. Bridges et al., Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation, BMC Cancer, vol.12, p.584, 2012.

C. Zen, Y. Zen, R. R. Mitry, D. Corbeil, J. Karbanova et al., Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation, Liver Transplant, vol.17, pp.943-954, 2011.

J. Cheng, M. Li, and Y. Lv, Sublethal heat treatment promotes epithelialmesenchymal transition and enhances the malignant potential of hepatocellular carcinoma, Hepatology, vol.59, p.1650, 2014.

L. H. Engelholm, A. Riaz, D. Serra, F. Dagnaes-hansen, J. V. Johansen et al., CRISPR/Cas9 engineering of adult mouse liver demonstrates that the dnajb1-prkaca gene fusion is sufficient to induce tumors resembling fibrolamellar hepatocellular carcinoma, Gastroenterology, vol.153, pp.1662-1673, 1610.

E. R. Kastenhuber, G. Lalazar, S. L. Houlihan, D. F. Tschaharganeh, T. Baslan et al., DNAJB1-PRKACA fusion kinase interacts with betacatenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma, PNAS, vol.114, pp.13076-13084, 2017.

G. G. Malouf, T. Tahara, V. Paradis, M. Fabre, C. Guettier et al., Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features, Epigenetics, vol.10, pp.872-881, 2015.

O. L. Griffith, M. Griffith, K. Krysiak, V. Magrini, A. Ramu et al., A genomic case study of mixed fibrolamellar hepatocellular carcinoma, Ann Oncol, vol.27, pp.1148-1154, 2016.

G. G. Malouf, L. Brugieres, L. Deley, M. C. Faivre, S. Fabre et al., Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection, Cancer, vol.118, pp.4981-4990, 2012.

G. G. Malouf, S. Job, V. Paradis, M. Fabre, L. Brugieres et al., Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature, Hepatology, vol.59, pp.2228-2237, 2014.

T. Oikawa, E. Wauthier, T. A. Dinh, S. R. Selitsky, A. Reyna-neyra et al., Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells, Nat Commun, vol.6, p.8070, 2015.

A. Moeini, D. Sia, Z. Zhang, G. Camprecios, A. Stueck et al., Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity, J Hepatol, vol.66, pp.952-961, 2017.

A. Wang, L. Wu, J. Lin, L. Han, J. Bian et al., Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma, Nat Commun, vol.9, p.894, 2018.

M. Kojiro, S. Sugihara, S. Kakizoe, O. Nakashima, and K. Kiyomatsu, Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy, Cancer Chemother Pharmacol, vol.23, pp.4-8, 1989.

C. Nakanishi, K. Sato, Y. Ito, T. Abe, T. Akada et al., Combined hepatocellular carcinoma and neuroendocrine carcinoma with sarcomatous change of the liver after transarterial chemoembolization, Hepatol Res, vol.42, pp.1141-1145, 2012.

L. D. Wood, C. M. Heaphy, H. D. Daniel, B. V. Naini, C. R. Lassman et al., Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features, Mod Pathol, vol.26, pp.1586-1593, 2013.

A. J. Cesare and R. R. Reddel, Alternative lengthening of telomeres: models, mechanisms and implications, Nat Rev Genet, vol.11, pp.319-330, 2010.

C. M. Heaphy, R. F. De-wilde, Y. Jiao, A. P. Klein, B. H. Edil et al., Altered telomeres in tumors with ATRX and DAXX mutations, Science, vol.333, p.425, 2011.

J. Schwartzentruber, A. Korshunov, X. Y. Liu, D. T. Jones, E. Pfaff et al., Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma, Nature, vol.482, pp.226-231, 2012.

H. Nagata, S. Komatsu, W. Takaki, T. Okayama, Y. Sawabe et al., Granulocyte colony-stimulating factor-producing hepatocellular carcinoma with abrupt changes, World J Clin Oncol, vol.7, pp.380-386, 2016.

K. Aita and K. Seki, Carcinosarcoma of the liver producing granulocytecolony stimulating factor, Pathol Int, vol.56, pp.413-419, 2006.

S. Joshita, K. Nakazawa, S. Koike, A. Kamijo, K. Matsubayashi et al., A case of granulocyte-colony stimulating factor-producing hepatocellular carcinoma confirmed by immunohistochemistry, J Korean Med Sci, vol.25, pp.476-480, 2010.

Z. Wang, T. B. Kim, B. Peng, J. Karam, C. Creighton et al., Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile, and transcriptional landscape, Clin Cancer Res, vol.23, pp.6686-6696, 2017.

Y. Klaile, K. Schlack, M. Boegemann, J. Steinestel, A. J. Schrader et al., Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?, Transl Androl Urol, vol.5, pp.692-701, 2016.

D. L. Willis, T. W. Flaig, D. E. Hansel, M. I. Milowsky, R. L. Grubb et al., Micropapillary bladder cancer: current treatment patterns and review of the literature, Urol Oncol, vol.32, pp.826-832, 2014.

K. Tsuchiya, M. Komuta, Y. Yasui, N. Tamaki, T. Hosokawa et al., Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation, Oncology, vol.80, pp.278-288, 2011.

H. Kim, G. H. Choi, D. C. Na, E. Y. Ahn, G. I. Kim et al., Human hepatocellular carcinomas with ''Stemness"-related marker expression: keratin 19 expression and a poor prognosis, Hepatology, vol.54, pp.1707-1717, 2011.

X. R. Yang, Y. Xu, G. M. Shi, J. Fan, J. Zhou et al., Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection, Clin Cancer Res, vol.14, pp.3850-3859, 2008.

S. H. Liao, T. H. Su, Y. M. Jeng, P. C. Liang, D. S. Chen et al., Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma, Hepatology, 2018.

W. H. Fridman, M. C. Dieu-nosjean, F. Pages, I. Cremer, D. Damotte et al., The immune microenvironment of human tumors: general significance and clinical impact, Cancer Microenviron, vol.6, pp.117-122, 2013.

W. H. Fridman, L. Zitvogel, C. Sautes-fridman, and G. Kroemer, The immune contexture in cancer prognosis and treatment, Nat Rev Clin Oncol, 2017.

W. Yao, J. C. He, Y. Yang, J. M. Wang, Y. W. Qian et al., The prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: a systematic review and meta-analysis, Sci Rep, vol.7, p.7525, 2017.

Y. Kurebayashi, H. Ojima, H. Tsujikawa, N. Kubota, J. Maehara et al., Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification, Hepatology, vol.68, pp.1025-1041, 2018.

J. Calderaro, F. Petitprez, E. Becht, A. Laurent, T. Z. Hirsch et al., Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma, J Hepatol, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02536028

M. Teufel, H. Seidel, K. Kochert, G. Meinhardt, R. S. Finn et al., Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma, Gastroenterology, vol.156, pp.1731-1741, 2019.

R. Pinyol, R. Montal, L. Bassaganyas, D. Sia, T. Takayama et al., Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial, 2018.

J. M. Llovet and V. Hernandez-gea, Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design, Clin Cancer Res, vol.20, pp.2072-2079, 2014.

J. M. Llovet, T. Decaens, J. L. Raoul, E. Boucher, M. Kudo et al., Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study, J Clin Oncol, vol.31, pp.3509-3516, 2013.

L. Rimassa, E. Assenat, M. Peck-radosavljevic, M. Pracht, V. Zagonel et al., Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study, Lancet Oncol, vol.19, pp.682-693, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02337178

S. Rebouissou, L. Bella, T. Rekik, S. Imbeaud, S. Calatayud et al., Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro, Clin Cancer Res, vol.23, pp.4364-4375, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02450533

A. X. Zhu, Y. K. Kang, C. J. Yen, R. S. Finn, P. R. Galle et al., Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, vol.20, pp.282-296, 2019.

M. Kudo, Systemic therapy for hepatocellular carcinoma: latest advances, Cancers (Basel), vol.10, 2018.

M. Inarrairaegui, I. Melero, and B. Sangro, Immunotherapy of hepatocellular carcinoma: facts and hopes, Clin Cancer Res, vol.24, pp.1518-1524, 2018.

A. X. Zhu, R. S. Finn, E. J. Cattan, S. Ogasawara, S. Palmer et al., Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial, Lancet Oncol, vol.19, pp.940-952, 2018.

S. P. Patel and R. Kurzrock, PD-L1 expression as a predictive biomarker in cancer immunotherapy, Mol Cancer Ther, vol.14, pp.847-856, 2015.

F. Pages, B. Mlecnik, F. Marliot, G. Bindea, F. S. Ou et al., International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study, Lancet, vol.391, pp.2128-2139, 2018.

V. Thorsson, D. L. Gibbs, S. D. Brown, D. Wolf, D. S. Bortone et al., The Immune landscape of cancer, Immunity, vol.48, pp.812-830, 2018.

B. Wang, T. Tian, K. H. Kalland, X. Ke, and Y. Qu, Targeting Wnt/beta-catenin signaling for cancer immunotherapy, Trends Pharmacol Sci, vol.39, pp.648-658, 2018.

S. Spranger, R. Bao, and T. F. Gajewski, Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity, Nature, vol.523, pp.231-235, 2015.

J. J. Havel, D. Chowell, and T. A. Chan, The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy, Nat Rev Cancer, vol.19, pp.133-150, 2019.

M. Yi, D. Jiao, H. Xu, Q. Liu, W. Zhao et al., Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors, Mol Cancer, vol.17, p.129, 2018.

G. T. Gibney, L. M. Weiner, and M. B. Atkins, Predictive biomarkers for checkpoint inhibitor-based immunotherapy, Lancet Oncol, vol.17, pp.542-551, 2016.

C. Q. Liu, J. Xu, Z. G. Zhou, L. L. Jin, X. J. Yu et al., Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma, Br J Cancer, vol.119, pp.80-88, 2018.

M. Torbenson and P. Schirmacher, Liver cancer biopsy-back to the future?, Hepatology, vol.61, pp.431-433, 2015.

, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, vol.373, p.1582, 2015.

A. T. Shaw, D. W. Kim, K. Nakagawa, T. Seto, L. Crino et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, vol.368, pp.2385-2394, 2013.

T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, vol.350, pp.2129-2139, 2004.

D. T. Le, J. N. Uram, H. Wang, B. R. Bartlett, H. Kemberling et al., PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, vol.372, pp.2509-2520, 2015.

P. B. Chapman, A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, vol.364, pp.2507-2516, 2011.

M. Sherman and J. Bruix, Biopsy for liver cancer: how to balance research needs with evidence-based clinical practice, Hepatology, vol.61, pp.433-436, 2015.

S. Torrecilla, D. Sia, A. N. Harrington, Z. Zhang, L. Cabellos et al., Trunk mutational events present minimal intra-and intertumoral heterogeneity in hepatocellular carcinoma, J Hepatol, vol.67, pp.1222-1231, 2017.

A. Villanueva, Y. Hoshida, C. Battiston, V. Tovar, D. Sia et al., Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma, Gastroenterology, vol.140, pp.1501-1512, 2011.

A. Lievre, J. B. Bachet, L. Corre, D. Boige, V. Landi et al., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, vol.66, pp.3992-3995, 2006.

A. M. Goodman, S. Kato, L. Bazhenova, S. P. Patel, G. M. Frampton et al., Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers, Mol Cancer Ther, vol.16, pp.2598-2608, 2017.

M. Yarchoan, A. Hopkins, and E. M. Jaffee, Tumor Mutational Burden and Response Rate to PD-1 Inhibition, N Engl J Med, vol.377, pp.2500-2501, 2017.

M. D. Hellmann, M. K. Callahan, M. M. Awad, E. Calvo, P. A. Ascierto et al., Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer, Cancer Cell, vol.33, pp.853-861, 2018.

N. A. Rizvi, M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov et al., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.348, pp.124-128, 2015.

S. Paik, S. Shak, G. Tang, C. Kim, J. Baker et al., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, vol.351, pp.2817-2826, 2004.

J. A. Sparano, R. J. Gray, D. F. Makower, K. I. Pritchard, K. S. Albain et al., Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer, N Engl J Med, 2018.

J. E. Rosenberg, J. Hoffman-censits, T. Powles, M. S. Van-der-heijden, A. V. Balar et al., Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, vol.387, pp.1909-1920, 2016.

A. Kuijer, M. Straver, B. Den-dekker, A. Van-bommel, S. G. Elias et al., Impact of 70-gene signature use on adjuvant chemotherapy decisions in patients with estrogen receptor-positive early breast cancer: results of a prospective cohort study, J Clin Oncol, vol.35, pp.2814-2819, 2017.

J. C. Nault, A. De-reynies, A. Villanueva, J. Calderaro, S. Rebouissou et al., A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection, Gastroenterology, vol.145, pp.176-187, 2013.

M. Reck, D. Rodriguez-abreu, A. G. Robinson, R. Hui, T. Csoszi et al., Pembrolizumab versus chemotherapy for PD-L1-positive nonsmall-cell lung cancer, N Engl J Med, vol.375, pp.1823-1833, 2016.

D. Abreu, F. B. Schwartz, G. N. Wells, W. A. Tsongalis, and G. J. , Personalized therapy for breast cancer, Clin Genet, vol.86, pp.62-67, 2014.

S. Lantuejoul, J. Adam, N. Girard, M. Duruisseaux, A. Mansuet-lupo et al., PD-L1 testing in non-small cell lung carcinoma: guidelines from the PATTERN group of thoracic pathologists, Ann Pathol, vol.38, pp.110-125, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01927078

J. I. Warrick, Clinical significance of histologic variants of bladder cancer, J Natl Compr Canc Netw, vol.15, pp.1268-1274, 2017.

N. E. Mouallem, S. C. Smith, and A. K. Paul, Sarcomatoid renal cell carcinoma: Biology and treatment advances, Urologic Oncol, vol.36, pp.265-271, 2018.

N. M. Tannir, E. Jonasch, L. Albiges, E. Altinmakas, C. S. Ng et al., Everolimus versus sunitinib prospective evaluation in metastatic nonclear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial, Eur Urol, vol.69, pp.866-874, 2016.

A. Maiti, M. Nemati-shafaee, P. Msaouel, L. C. Pagliaro, E. Jonasch et al., Phase 2 trial of capecitabine, gemcitabine, and bevacizumab in sarcomatoid renal-cell carcinoma, Clin Genitourin Cancer, 2017.

D. Komura and S. Ishikawa, Machine learning methods for histopathological image analysis, Comput Struct Biotechnol J, vol.16, pp.34-42, 2018.

K. H. Yu, C. Zhang, G. J. Berry, R. B. Altman, C. Re et al., Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features, Nat Commun, vol.7, p.12474, 2016.

P. Mobadersany, S. Yousefi, M. Amgad, D. A. Gutman, J. S. Barnholtz-sloan et al., Predicting cancer outcomes from histology and genomics using convolutional networks, PNAS, vol.115, pp.2970-2979, 2018.

U. Djuric, G. Zadeh, K. Aldape, and P. Diamandis, Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care, NPJ Precis Oncol, vol.1, p.22, 2017.

J. N. Kather, J. Krisam, P. Charoentong, T. Luedde, E. Herpel et al., Predicting survival from colorectal cancer histology slides using deep learning: a retrospective multicenter study, PLoS Med, vol.16, p.1002730, 2019.

J. W. Wei, L. J. Tafe, Y. A. Linnik, L. J. Vaickus, N. Tomita et al., Pathologist-level classification of histologic patterns on resected lung adenocarcinoma slides with deep neural networks, Sci Rep, vol.9, p.3358, 2019.

N. Coudray, P. S. Ocampo, T. Sakellaropoulos, N. Narula, M. Snuderl et al., Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning, Nat Med, vol.24, pp.1559-1567, 2018.